8-K: Bio-Techne Reports Mixed Q1 Results with Strong Growth in Diagnostics and Spatial Biology Segment

Bio-Techne's first quarter fiscal 2025 results show a 5% increase in revenue, driven by strong growth in the Diagnostics & Spatial Biology segment, but a decrease in GAAP earnings per share.

Summary

• Bio-Techne reported a 5% increase in net sales to $289.5 million for the first quarter of fiscal year 2025.
• Organic revenue growth was 4%, with a 1% positive impact from foreign currency exchange.
• GAAP earnings per share (EPS) decreased to $0.21 from $0.31 in the same quarter last year.
• Adjusted EPS increased slightly to $0.42 from $0.41 year-over-year.
• The Diagnostics & Spatial Biology segment saw a 14% increase in revenue, while the Protein Sciences segment remained flat.
• GAAP operating income decreased by 28% to $40.0 million, and GAAP operating margin was 13.8%.
• Adjusted operating income decreased by 4%, and adjusted operating margin was 29.0%.
• The company declared a cash dividend of $0.08 per share for the quarter ended September 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While there is strong growth in the Diagnostics & Spatial Biology segment and a dividend was declared, the decrease in GAAP earnings and operating income is concerning. The company is navigating a challenging industry environment.

Positives

• The Diagnostics & Spatial Biology segment showed strong growth with a 14% increase in revenue.
• The company saw continued uptake of cell and gene therapy workflow solutions.
• There was robust growth in the company's GMP reagent portfolio.
• The company's management expressed increased confidence in the recovery of the biotech end market due to favorable funding dynamics.
• The company declared a cash dividend of $0.08 per share.

Negatives

• GAAP earnings per share decreased to $0.21 from $0.31 year-over-year.
• GAAP operating income decreased by 28% to $40.0 million.
• GAAP operating margin decreased to 13.8% from 20.2% in the same quarter last year.
• Adjusted operating income decreased by 4% compared to the first quarter of fiscal 2024.
• Adjusted operating margin decreased to 29.0% from 31.4% in the same quarter last year.
• The Protein Sciences segment remained flat year-over-year.

Risks

• The company faces risks related to new branding and marketing initiatives.
• Integration of new businesses and leadership could pose challenges.
• The introduction and acceptance of new products is uncertain.
• Funding and focus of research by the company's customers can fluctuate.
• The company faces competition from a growing number of biotechnology research product producers.
• General economic conditions and currency exchange rate fluctuations can impact results.
• The costs and results of research and product development efforts are uncertain.

Future Outlook

The company anticipates a recovery in the biotech end market due to favorable funding dynamics and expects continued growth in its core portfolio and growth pillars.

Management Comments

• The start to fiscal 2025 was largely consistent with our expectations, as a high-level of execution by the Bio-Techne team drove continued momentum across our Diagnostics & Spatial Biology segment, said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.
• Our growth pillars, as well as our core portfolio, continue to outperform in what has proven to be a prolonged period of challenges facing the industry.
• We remain focused on delivering the solutions our customers rely on to catalyze advances in science and medicine while creating value for all our stakeholders.

Industry Context

The company's performance is being viewed in the context of a challenging period for the broader biotechnology industry, with Bio-Techne highlighting its ability to outperform despite these headwinds. The growth in the Diagnostics & Spatial Biology segment reflects the increasing importance of these areas in the life sciences sector.

Comparison to Industry Standards

• Bio-Techne's 4% organic revenue growth is a mixed result compared to other life science companies, some of which have seen higher growth rates in specific segments like diagnostics and spatial biology.
• Companies like Danaher and Thermo Fisher Scientific, which have a broader portfolio, have reported varying growth rates across their segments, with some areas experiencing higher growth than Bio-Techne's Protein Sciences segment.
• The 14% growth in Bio-Techne's Diagnostics & Spatial Biology segment is competitive with other companies focused on these areas, such as 10x Genomics, which has seen significant growth in spatial biology.
• Bio-Techne's adjusted operating margin of 29.0% is within the range of other life science companies, but some companies with higher-margin businesses may have higher operating margins.
• The decrease in GAAP EPS and operating income is a concern, as other companies in the sector have been focused on improving profitability.

Stakeholder Impact

• Shareholders will receive a cash dividend of $0.08 per share.
• The company's performance impacts investor confidence and share price.
• Employees are affected by the company's financial performance and strategic direction.
• Customers benefit from the company's products and services.
• Suppliers and creditors are impacted by the company's financial health.

Next Steps

• The company will host an earnings conference call on October 30, 2024, at 8:00 a.m. CDT.
• The Board of Directors will consider future cash dividends on a quarterly basis.

Key Dates

Keywords

Bio-Techne, Diagnostics, Spatial Biology, Protein Sciences, Cell and Gene Therapy, Reagents, Dividend, Financial Results, Earnings, Revenue, EPS, Operating Margin